Leaders in their fields, our scientists are deeply committed to the discovery and development of new medicines to address areas of serious need for patients. Leveraging our deep understanding of the biology of hemostasis gained over 15 years of research, we plan to accelerate the development of our innovative pipeline of programs in hemophilia, sickle cell disease and other rare blood disorders.
Our pipeline includes hemophilia programs that have been designed to provide less-frequent prophylactic dosing for hemophilia A and subcutaneous dosing for hemophilia B.
We are also pursuing several approaches that seek to target the root cause of sickle cell disease, a profoundly debilitating disease that is linked to a shorter life expectancy and has few treatment options. Just as we have done in hemophilia, we hope to bring forward new medicines that meaningfully advance the treatment of people with sickle cell disease.